Brentuximab vedotin consolidation post-autologous stem cell transplant in Hodgkin lymphoma patients at risk of residual disease: number needed to treat

Autor: Vijayveer Bonthapally, Akshara Richhariya, Jeremy Teasell, Shih-Yuan Lee, Ashish Gautam, Yanyan Zhu, Esprit Ma, Dirk Huebner, Erin Zagadailov
Rok vydání: 2017
Předmět:
Adult
Male
Oncology
Cancer Research
medicine.medical_specialty
Immunoconjugates
Neoplasm
Residual
Adolescent
CD30
medicine.medical_treatment
Population
Hematopoietic stem cell transplantation
Disease
Placebo
Transplantation
Autologous
Young Adult
03 medical and health sciences
Antineoplastic Agents
Immunological
0302 clinical medicine
Risk Factors
Internal medicine
medicine
Humans
030212 general & internal medicine
education
Brentuximab vedotin
Aged
Proportional Hazards Models
Brentuximab Vedotin
education.field_of_study
business.industry
Hematopoietic Stem Cell Transplantation
Hematology
Middle Aged
Combined Modality Therapy
Hodgkin Disease
Intention to Treat Analysis
Surgery
Consolidation Chemotherapy
Treatment Outcome
030220 oncology & carcinogenesis
Disease Progression
Number needed to treat
Female
Stem cell
business
medicine.drug
Zdroj: Leukemia & Lymphoma. 59:69-76
ISSN: 1029-2403
1042-8194
Popis: The number needed to treat (NNT) with brentuximab vedotin consolidation therapy post-autologous stem cell transplant (ASCT) versus placebo in the phase 3 AETHERA trial to avoid one additional event of disease progression/death was evaluated. AETHERA included 329 Hodgkin lymphoma patients at increased risk of progression post-ASCT who received brentuximab vedotin 1.8 mg/kg (n = 165) or placebo (n = 164) on day 1 of each 21-d cycle (up to 16 cycles). Over 60 months, the NNT with brentuximab vedotin ranged from 4.08 to 7.79 for the intent-to-treat population, 3.18–6.07 for patients with ≥2 risk factors, and 2.98–5.65 for patients with ≥3 risk factors. At various time points, and dependent on the risk group, 3–8 patients would need to be treated with brentuximab vedotin consolidation therapy to prevent a disease progression/death, compared with placebo. Patients with increased risk of relapse may benefit most from brentuximab vedotin.
Databáze: OpenAIRE
Externí odkaz: